|
View this as a webpage
Minnesota Department of Health
September 15, 2022
We recently heard from CDC that Moderna bivalent booster (18+) allocations will arrive later than initially anticipated. As a result, we have temporarily removed Moderna bivalent boosters from ordering in MIIC. We will notify providers when Moderna bivalent boosters will be available for ordering again and ask providers to place their orders at that time. We suggest placing an order for Pfizer bivalent vaccine (12+) with minimum shipment quantity of 300 doses in MIIC if you would like to receive vaccine within the next 2 weeks. Please contact health.mdhvaccine@state.mn.us with questions.
The Pfizer bivalent booster (12+) and Moderna bivalent booster (18+) has been added to the Find COVID-19 vaccine locations tool. We strongly encourage you to use the provider site intake form to add and modify your vaccination sites when you are ready to administer bivalent booster vaccine formulations. Sites are also able to differentiate between offering primary series and booster presentations in the 12+ age group. Options will include specific age groups you serve, based on your provider type.
Questions on the Find COVID-19 vaccine locations tool can be directed to Julie Viken at julie.viken@state.mn.us and Anthony Jumelles at anthony.jumelles.c19@state.mn.us.
With the monovalent COVID-19 vaccine no longer being authorized as a booster dose for people age 12 and older effective August 31, any monovalent mRNA COVID-19 vaccine booster administration to people 12 and older must be reported to CDC’s Vaccine Adverse Event Reporting System (VAERS).
With the flu season fast approaching, remember that CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines supports administering COVID-19 vaccine with other vaccines, including flu, on the same day. When deciding whether to administer other vaccine(s) with COVID-19 vaccine, vaccination providers should consider whether the patient is behind, or at risk of becoming behind, on recommended vaccines; their risk of the vaccine-preventable disease; and the reactogenicity profile of the vaccines. Administer COVID-19 vaccines and vaccines that may be more likely to cause a local reaction in different limbs, if possible. For more information, please review best practices for administering multiple injections at CDC Administer the Vaccine(s).
|
